| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ticagrelor |
| Brand | Brilique® |
| Indication | For the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft). |
| Assessment Process | |
| Rapid review commissioned | 25/11/2010 |
| Rapid review completed | 20/01/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/07/2011 |
| NCPE assessment completed | 10/10/2011 |
| NCPE assessment outcome | Reimbursement Recommended |
We consider Ticagrelor (Brilique®) a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG.
